AE37 peptide vaccine
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AE37 peptide vaccine, covering 2021-06-02 to 2021-06-02. Get the full timeline:
Most recent: Clinical Trial Update: Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer [Phase 2]